Baird downgrades Acorda Therapeutics (Nasdaq: ACOR) to Neutral, retains $32 price target.

Baird analyst says, "Moving to the sidelines as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE